Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Destiny Pharma Ltd
Destiny Pharma Ltd
Activities:
Ingredients
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Drug Delivery
Positive update on the development of new XF‐platform drug formulations
Collaboration with MedPharm delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections
Research & Development
Destiny Pharma secures £1.6 million grant to fight microbial resistance
The UK-China antimicrobial resistance programme has allocated grant to research its novel XF drugs
Recruitment
Nick Rodgers joins Destiny Pharma
Research & Development
Destiny Pharma announces research collaboration with Aston University
Partnership will see a dedicated team investigate potential antimicrobial candidates against biofilms
Media
Destiny Pharma establishes Scientific Advisory Board
Pharmaceutical
Destiny Pharma appoints Neil Clark new CEO
Bill Love, Destiny’s founder, to become Chief Scientific Officer
Ingredients
Destiny Pharma receives US FDA QIDP designation for novel antibacterial product
Lead drug product in development for the prevention of post-surgical Staphyloccocal infections
Subscribe now